Pomalyst 2 MG, 3MG, 4 MG
Ended Awarded Last action
- Contract number
- 36C24526N0315
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $94,326
Award facts
- Contract value 100% obligated
- $94,325.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $782 | |
| Original award | $93,543 |
About this award
Bristol-Myers Squibb Company has been awarded a delivery order valued at $94,325.50 under its Federal Supply Schedule contract for the supply of Pomalyst (pomalidomide) in multiple dosage strengths (2 mg, 3 mg, and 4 mg formulations) to the Department of Veterans Affairs' Veterans Integrated Service Network 5. This firm fixed-price BPA call order was awarded on February 11, 2026, with an ultimate completion date of February 13, 2026, and will be performed in Memphis, Tennessee. The delivery order represents a continuation of Bristol-Myers Squibb's established role as a critical pharmaceutical supplier to the VA healthcare system, providing specialized oncology treatments to eligible veterans.
This delivery order is issued under Bristol-Myers Squibb's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule master contract (36F79724D0101), which carries a substantial ceiling value of $12.28 billion and extends through April 30, 2029. The FSS contract, awarded to the large pharmaceutical manufacturer without set-aside designation, encompasses a comprehensive portfolio of drugs and therapeutics across multiple therapeutic areas. Since 2022, the VA has issued more than 50 documented delivery orders to Bristol-Myers Squibb through this vehicle, reflecting sustained procurement demand for the company's advanced oncology and cell therapy products that support the agency's mission to provide state-of-the-art cancer treatments and specialized medical care to the veteran population.
Quick answers
Who was awarded contract 36C24526N0315?
36C24526N0315 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 11, 2026.
How much is contract 36C24526N0315 worth?
The government has obligated $94,326 on 36C24526N0315.
Is contract 36C24526N0315 an order under another contract?
Yes. 36C24526N0315 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0315 competed?
The extent of competition for 36C24526N0315 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award